Market Research Logo

Chronic Obstructive Pulmonary Disorder (COPD): Update Bulletin [Feb 2016]

Chronic Obstructive Pulmonary Disorder (COPD): Update Bulletin [Feb 2016]

Introduction

This edition presents key opinion leader (KOL) views on recent developments in the chronic obstructive pulmonary disease (COPD) market. Topics covered include the clinical role of MABAs (muscarinic antagonists/beta2 agonists), with GlaxoSmithKline recently initiating Phase II trails with batefenterol, including a combination study with an ICS (fluticasone furoate). KOL’s views of asthma COPD overlap syndrome (ACOS) are explored, including the prospects for GSK’s ICS/LAMA combination that was tested specifically in patients with ACOS. Novartis is developing a “smart” Breezhaler/Neohaler device that electronically captures adherence data: KOLs assess how this novel feature might improve adherence.

Key Questions Answered in this Update Bulletin:

What is the role of MABAs (muscarinic antagonists/beta2 agonists) and what advantages do they offer over current bronchodilators?
What is the rationale for developing MABA/ICS combinations?
Will MABA/ICS provide similar benefits to the more clinically advanced LAMA/LABA/ICS combinations?
Could a MABA be combined with an ICS and an additional anti-inflammatory agent?
Will asthma COPD overlap syndrome (ACOS) be recognized by physicians or regulators as a distinct clinical entity?
Could Novartis’s novel ‘Smart’ Breezhaler/Neohaler device improve adherence?

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.


Please Note: Due to the brevity and/or nature of the content posted, there is no table of contents available for this report.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report